Phase III Trial of Cetuximab, Bevacizumab, and 5-Fluorouracil/Leucovorin vs. FOLFOX-Bevacizumab in Colorectal Cancer-Reference-Cited by-同舟云学术

Phase III Trial of Cetuximab, Bevacizumab, and 5-Fluorouracil/Leucovorin vs. FOLFOX-Bevacizumab in Colorectal Cancer

Published:2012-06 Issue:2 Volume:11 Page:101-111
ISSN:1533-0028
Container-title:Clinical Colorectal Cancer
language:en
Short-container-title:Clinical Colorectal Cancer

Author:

Saltz Leonard,Badarinath Suprith,Dakhil Shaker,Bienvenu Bryan,Harker W. Graydon,Birchfield George,Tokaz Laurence K.,Barrera David,Conkling Paul R.,O'Rourke Mark A.,Richards Donald A.,Reidy Diane,Solit David,Vakiani Efsevia,Capanu Marinella,Scales Amy,Zhan Feng,Boehm Kristi A.,Asmar Lina,Cohn Allen

Publisher

Elsevier BV

Subject

Gastroenterology,Oncology

Reference14 articles.

1. Different strategies of sequential and combination chemotherapy for patients with poor prognosis advanced colorectal cancer (MRC FOCUS): a randomized controlled trial;Seymour;Lancet,2007

2. Sequential versus combination chemotherapy with capecitabine, irinotecan, and oxaliplatin in advanced colorectal cancer (CAIRO): a phase III randomised controlled trial;Koopman;Lancet,2007

3. Randomized phase II trial of cetuximab, bevacizumab, and irinotecan compared with cetuximab and bevacizumab alone in irinotecan-refractory colorectal cancer: the BOND-2 study;Saltz;J Clin Oncol,2007

4. Nomenclature and Criteria for Diagnosis of Diseases of the Heart and Great Vessels,1994

5. New guidelines to evaluate the response to treatment in solid tumors;Therasse;J Natl Cancer Inst,2000

Cited by 61 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Tumor angiogenesis and anti-angiogenic therapy;Chinese Medical Journal;2024-07-25

2. Anti-vascular endothelial growth factor receptor in colorectal cancer: A review;International Journal of Gastrointestinal Intervention;2023-07-31

3. Long-term Survival Update and Extended RAS Mutational Analysis of the CAIRO2 Trial: Addition of Cetuximab to CAPOX/Bevacizumab in Metastatic Colorectal Cancer;Clinical Colorectal Cancer;2023-03

4. Phase IIIb study of the bevacizumab biosimilar candidate BI 695502 plus mFOLFOX6 in metastatic colorectal cancer;Colorectal Cancer;2022-11-09

5. A randomized, double-blind, single-dose, parallel phase I clinical trial to compare the bioequivalence, immunogenicity, and safety of bevacizumab biosimilar and bevacizumab in healthy Chinese subjects;Expert Opinion on Drug Metabolism & Toxicology;2022-08-03